[{"id":"3c19bae1-0bb5-4981-9c9a-f622527c42f9","acronym":"MCLA-158-CL01","url":"https://clinicaltrials.gov/study/NCT03526835","created_at":"2023-02-28T17:01:26.541Z","updated_at":"2025-02-25T17:36:01.506Z","phase":"Phase 1/2","brief_title":"A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03526835 - MCLA-158-CL01","lead_sponsor":"Merus N.V.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • petosemtamab (MCLA-158)"],"overall_status":"Recruiting","enrollment":" Enrollment 523","initiation":"Initiation: 05/02/2018","start_date":" 05/02/2018","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-01-29"}]